

(Use several sheets if necessary)

Sheet 1 of 1

Application Number	10/802,432
Filing Date	March 17, 2004
First Name Inventor	Certa
Group Art Unit	
Examiner Name	
Attorney Docket Number	21574

U.S. PATENT DOCUMENTS

[illegible]

FOREIGN PATENT DOCUMENTS

Examiner Initials'	Cite No.'	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	T'
		Office ³	Number ⁴	Kind Code ⁵ (if known)			
JSB	B1	EP0834575			Affymetrix, Inc.	11-28-2001	
JSB	B2	EP0834576			Affymetrix, Inc.	01-16-2002	
JSB	B3	EP0510356			F. Hoffman-La Roche AG	01-27-1999	
JSB	B4	EP0593868			F. Hoffman-La Roche AG	04-15-1998	
JSB	B5	EP0809996			F. Hoffman-La Roche AG	04-02-2003	
JSB	B6	WO96/31622			ISIS INNOVATION LIMITED	10-10-1996	
JSB	B7	WO98/30883			Affymetrix, Inc.	07-16-1998	
JSB	B8	WO97/10365			AFFYMAX TECHNOLOGIES N.V.	03-20-1997	
JSB	B9	WO02/18633			F. Hoffman-La Roche AG	03-07-2002	
Examiner Signature	Date Considered / John S. Brusca/				09/16/2006		

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Unique citation designation number. ²See attached Kinds of U.S. Patent Documents. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶Applicant is to place a check mark here if English language Translation or abstract is attached.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)				Substitute for form 1449A/PTO	
				Complete if Known	
				Application Number	10/802,432
				Filing Date	March 17, 2004
				First Name Inventor	Certa
				Group Art Unit	
				Examiner Name	
Sheet	2	Of	2	Attorney Docket Number	21574

NON PATENT LITERATURE DOCUMENTS

Examiner Initials [*]	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T ²
JSB	C1	P. BAILON et al., Rational design of a potent, long-lasting form of interferon: A 40 kDa branched polyethylene glycol0conjugated Interferon-2a for the treatment of hepatitis C, Bioconjugate Chem. 12 (2001), 195-202	
JSB	C2	Z.Z. CHONG, et al., Hematopoietic factor erythropoietin foster neuroprotection through novel signal transduction cascades, J. Cereb.Blood Flow Metab., 22 (2002), 503-514	
JSB	C3	CK GLASS: Some new twists in the regulation of gene expression by throid hormone and retinoic acid receptors, J. Endorinol, 150 (1996), 349-357	
JSB	C4	T. HANADA and A. YOSHIMURA: Regulation of cytokine signaling and inflammation, Cytokine Growth Factor Rev., 13 (2002), 413-421	
JSB	C5	J.M. HARRIS, et. al., Pegylation: A novel process for modifying pharmacokinetics, Clin. Pharmacokinet. 40 (2001), 539-551	
JSB	C6	KLAUS, et al., J. Mol. Biol. 274 (1997) 661-675	
JSB	C7	R. MANDLER et al., Modification in syntheses strategy..., Bioconjugate Chemistry, 13 (2002), 786-791	
JSB	C8	G.S. MCKNIGHT: Cyclic AMP second messenger systems, Curr. Opin. Cell Biol., 3 (1991) 213-217	
JSB	C9	L. MULCAHY: the erythropoietin receptor, Semin. Oncol. 28 (2001), 19-23	
JSB	C10	Y. NISHIO, et al., Cilostazol, a cAMP phosphodiesterase inhibitor..., Hormone & Metabolic Research, 29 (1997) 491-495	
JSB	C11	A. ROWE, Retinoid X Receptors, Int. J. Biochem. Cell Biol. 29 (1997), 275-278	
JSB	C12	Y. SATO et al., Properties of two VEGF receptors, Flt-1 and KDR, in signal transduction, Ann. N.Y. Acad. Sci., 902 (2000), 201-207	
JSB	C13	J.L. SPIVAK: The mechanism of action of erythropoietin, Int. J. Cell Cloning, 4 (1986) 139-166	
JSB	C14	A.H. TALUKDER et al, Antihuman epidermal growth factor..., Clin. Cancer Res. 8 (2002), 3285-3289	
JSB	C15	B. WAGNER, et al., 7-Benzylamino-6chloro-2piperazino-4-pyrrolidino-pteridine....Biochemical Pharmacology, 63 (2002) 659-668	
JSB	C16	D.M. WOJCHOWSKI and T.C. HE: Signal transduction in the erythropoietin receptor system, Stem. Cells, 11 (1993), 381-392	
Examiner Signature	/John S. Brusca/		DATE CONSIDERED 09/16/2006

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Unique citation designation number. ² Applicant is to place a check mark here if English language Translation or abstract is attached.

142861

Substitution for Form 1001 INFORMATION DISCLOSURE STATEMENT BY APPLICANT JUL 08 2005 (Use several sheets if necessary)			Complete if Known	
			Application Number	10/802,432
			Filing Date	March 17, 2004
			First Name Inventor	Certa
			Group Art Unit	1631
			Examiner Name	
Sheet	2	Of	Attorney Docket Number	21574

NON PATENT LITERATURE DOCUMENTS

[illegible]

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Unique citation designation number. ²Applicant is to place a check mark here if English language Translation or abstract is attached.

159262